Stockscreener 앱 받기
189.24
0.92%
1.73
전일 마감가:
$187.51
열려 있는:
$188.37
하루 거래량:
3.19M
Relative Volume:
0.95
시가총액:
$40.23B
수익:
$742.00K
순이익/손실:
$-1.37B
주가수익비율:
-26.75
EPS:
-7.0731
순현금흐름:
$-1.07B
1주 성능:
+6.21%
1개월 성능:
+25.07%
6개월 성능:
+139.48%
1년 성능:
+408.85%
1일 변동 폭
$184.28
$189.48
1주일 범위
$174.26
$193.09
52주 변동 폭
$34.00
$193.09
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
650-481-6801
주소
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-02-27 | 재개 | UBS | Buy |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-12 | 재개 | Raymond James | Strong Buy |
| 2025-09-05 | 개시 | Truist | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-08-15 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Revolution Medicines director Sushil Patel sells $1.05m in stock - Investing.com
Form 4 Revolution Medicines Inc For: 1 July By Investing.com - Investing.com Canada
Revolution Medicines director Sushil Patel sells $1.05m in stock By Investing.com - Investing.com Canada
Revolution Medicines (NASDAQ: RVMD) director sells 5,580 shares, exercises options - Stock Titan
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd. - Yahoo Finance
Price to sales forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Price to earnings forward of Revolution Medicines, Inc. – BMV:RVMD - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – MIL:1RVMD - TradingView
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
8-Day Rally Sends Revolution Medicines Stock Up 23% - Trefis
Price to earnings forward of Revolution Medicines, Inc. – MIL:1RVMD - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Revolution Medicines Price Target Raised to $235.00/Share From $183.00 by Needham - Moomoo
Revolution Medicines, Inc.(NasdaqGS:RVMD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Proposed sale of RVMD common shares reported (NASDAQ: RVMD) - Stock Titan
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - StreetInsider
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell Midcap Growth Benchmark - marketscreener.com
Price to sales forward of Revolution Medicines, Inc. – MIL:1RVMD - TradingView
RVMD Maintained by Needham -- Price Target Raised to $235 - GuruFocus
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces - GlobeNewswire
Revolution Medicines Is Maintained at Buy by Needham - Moomoo
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $215 - Moomoo
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell 3000E Growth Benchmark - marketscreener.com
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell 1000 Growth Benchmark - marketscreener.com
Revolution Medicines, Inc.(NasdaqGS: RVMD) dropped from Russell 2500 Index - marketscreener.com
Enterprise value to EBITDA forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Enterprise value to EBITDA forward of Revolution Medicines, Inc. – TRADEGATE:42Z - TradingView
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Insider Sell: Jack Anders Sells 20,000 Shares of Revolution Medi - GuruFocus
42Z Forecast — Price Target — Prediction for 2027 - TradingView
Revolution Medicines (RVMD) CFO trades 20K shares under 10b5-1 plan - Stock Titan
Revolution Medicines Faces 'Uphill Battle' in Potential Patent Claim Against Erasca, RBC Says - Moomoo
RBC Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $182 - Moomoo
Revolution Medicines, Inc. Actuals & Estimates (NASDAQ:RVMD) - TradingView
Revolution Medicines, Inc. Actuals & Estimates (BMV:RVMD) - TradingView
Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $188.57, Implies 11% Upside - TradingView
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Erasca, Inc. (ERAS) to Contact Law Firm - StreetInsider
Revolution Medicines, Inc. Actuals & Estimates (LSX:A2PYWG) - TradingView
Revolution Medicines rises as investors focus on fresh pancreatic cancer pipeline updates - Quiver Quantitative
J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $200 - Moomoo
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $212 - Moomoo
Truist Financial Maintains Revolution Medicines(RVMD.US) With Buy Rating - Moomoo
Revolution Medicines to Present Four RAS(ON) Pipeline Studies at 2026 ESMO Gastrointestinal Cancers Congress - Quiver Quantitative
Revolution Medicines to Present Clinical Data from RAS(ON) - GlobeNewswire
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 - Yahoo! Finance Canada
Form 144 Revolution Medicines For: 24 June By Investing.com - Investing.com Nigeria
A pancreatic cancer drug provides new hope: Five things to know about daraxonrasib - Stanford Medicine
Form 144 | Revolution Medicines(RVMD.US) Officer Proposes to Sell 3.39 Million in Common Stocks - Moomoo
Jack Anders (RVMD) files to sell 20,000 shares after option exercise - Stock Titan
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Revolution Medicines Inc 주식 (RVMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Patel Sushil | Director |
Jun 29 '26 |
Sale |
187.99 |
5,580 |
1,048,967 |
21,656 |
3.68%
자본화:
|
볼륨(24시간):